Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
9.89
+0.88 (9.71%)
Aug 28, 2026, 2:24 PM EDT - Market open
Akari Therapeutics, Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 7.69 | 5.2 | 2.6 | 3.85 | 13.25 | 9.36 |
Cash & Short-Term Investments | 7.69 | 5.2 | 2.6 | 3.85 | 13.25 | 9.36 |
Cash Growth | 183.81% | 100.19% | -32.41% | -70.98% | 41.54% | -33.40% |
Prepaid Expenses | 0.53 | 0.19 | 0.09 | 0.3 | 0.47 | 2.17 |
Restricted Cash | 0.06 | 0.06 | 0.06 | - | - | - |
Other Current Assets | 0.04 | 0.01 | 0.2 | 0.2 | 0.1 | 0.09 |
Total Current Assets | 8.32 | 5.46 | 2.95 | 4.34 | 13.82 | 11.63 |
Goodwill | - | 8.43 | 8.43 | - | - | - |
Other Intangible Assets | 30.3 | 34 | 39.18 | 0.01 | 0.02 | 0.02 |
Total Assets | 38.62 | 47.89 | 50.56 | 4.36 | 13.83 | 11.65 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 9.4 | 8.77 | 12.41 | 1.67 | 0.95 | 1.79 |
Accrued Expenses | 3.51 | 2.34 | 3.14 | 1.57 | 3.15 | 3.18 |
Short-Term Debt | 0.69 | 0.75 | 3.26 | - | - | - |
Other Current Liabilities | 0.33 | 0.49 | 1.11 | 1.35 | 7.95 | 1.12 |
Total Current Liabilities | 13.94 | 12.35 | 19.91 | 4.58 | 12.04 | 6.09 |
Long-Term Deferred Tax Liabilities | 6.09 | 6.95 | 8.04 | - | - | - |
Other Long-Term Liabilities | - | 0.26 | 0.38 | - | - | - |
Total Liabilities | 20.03 | 19.56 | 28.33 | 4.58 | 12.04 | 6.09 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | - | 5.32 | 1.32 | 0.75 | 0.48 |
Additional Paid-In Capital | 243.76 | 234.32 | 212.71 | 174.75 | 167.08 | 153.13 |
Retained Earnings | -283.81 | -264.55 | -247.25 | -227.46 | -217.45 | -199.71 |
Comprehensive Income & Other | 58.65 | 58.56 | 51.46 | 51.15 | 51.42 | 51.65 |
Shareholders' Equity | 18.6 | 28.33 | 22.23 | -0.23 | 1.79 | 5.55 |
Total Liabilities & Equity | 38.62 | 47.89 | 50.56 | 4.36 | 13.83 | 11.65 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.69 | 0.75 | 3.26 | - | - | - |
Net Cash (Debt) | 7 | 4.45 | -0.66 | 3.85 | 13.25 | 9.36 |
Net Cash Growth | 501.46% | - | - | -70.98% | 41.54% | -33.40% |
Net Cash Per Share | 5.41 | 5.29 | -2.21 | 31.42 | 169.78 | 174.48 |
Filing Date Shares Outstanding | 1.95 | 1.14 | 0.72 | 0.2 | 0.13 | 0.07 |
Total Common Shares Outstanding | 1.75 | 1.13 | 0.66 | 0.17 | 0.09 | 0.06 |
Working Capital | -5.61 | -6.89 | -16.96 | -0.24 | 1.77 | 5.53 |
Book Value Per Share | 10.62 | 25.03 | 33.44 | -1.38 | 19.25 | 93.36 |
Tangible Book Value | -11.71 | -14.1 | -25.38 | -0.24 | 1.77 | 5.53 |
Tangible Book Value Per Share | -6.69 | -12.46 | -38.18 | -1.47 | 19.06 | 92.97 |
Machinery | - | - | - | - | - | 0.16 |